Ipamorelin

1. What is it?

Ipamorelin is a synthetic peptide made of five amino acids. It triggers growth hormone release but is not GH itself. It activates a receptor also used by ghrelin, so researchers studied both hormonal effects and digestive function. Its name does not identify one approved product: chemical form, preparation quality and route of administration matter, and some older publications describe them incompletely. [78] [81]

2. Why do people turn to it?

Ipamorelin attracts interest because of hopes for improved body composition, recovery and sleep through growth hormone stimulation. The description selective is sometimes taken as a promise of greater safety. However, early studies are insufficient to establish such benefits in a healthy person exercising at a gym. [78] [81]

The most specific study of a potential medical use concerned the temporary slowing of bowel function after surgery. After major abdominal surgery, the digestive tract may work too slowly for a time, making it harder to eat and leave hospital. Researchers tested whether stimulating the ghrelin receptor would speed up the return of meal tolerance. This is a different problem from weight loss or rebuilding muscles after training. The fact that this trial was conducted must not be used as confirmation of every advertised use. [80]

3. How does it work?

In original 1998 experiments, ipamorelin stimulated GH release in rat pituitary cells and animals. In pigs, it was more selective for GH than some other peptides, without similarly stimulating ACTH and cortisol. This produced the frequently repeated description selective. A 1999 healthy-men study confirmed a short GH response after intravenous administration, but did not assess months-long improvements in strength, sleep or body composition. [78] [79]

4. What do studies actually show?

A randomised phase 2 trial published in 2014 involved adults who had undergone bowel resection, meaning surgery to remove part of the bowel. The main outcome was the time until they could tolerate a specified solid meal. The study did not confirm the expected effectiveness for this primary outcome. That matters more than selecting one favourable-looking measurement. Patients were monitored in hospital, and the intervention addressed a specific situation after surgery, so it does not describe everyday use by healthy people. [80]

5. What do we still not know?

The FDA noted that it found no adequate data on ipamorelin's absorption and effects by the proposed subcutaneous route. Existing intravenous data do not solve this problem: changing the route can alter how the substance reaches the blood and the response it produces. Reliable confirmation that ipamorelin treats GH deficiency in children or adults is also lacking. A mixture with another peptide needs its own assessment; it does not automatically inherit the findings for each ingredient separately. [81]

6. What are the risks?

Records from the postoperative trial included glucose and potassium disturbances, digestive symptoms and serious complications. Two participants receiving ipamorelin died after severe surgical complications. The FDA explicitly noted that it was unknown whether the deaths were related to the study substance. A fair account must retain both points. The regulator also noted a shortage of long-term toxicity studies and uncertainty about immune reactions and the quality of peptide products. [81]

In sport governed by WADA anti-doping rules, this substance is prohibited at all times, including outside competition. The 2026 list names it explicitly. Use during training or a break between competitions is also covered by the ban. [108]

7. Is it an approved medicine?

The FDA assessment prepared for the October 2024 meeting did not treat ipamorelin as an ingredient in an approved medicine for the uses discussed. It considered whether certain substances could be used in US pharmacy compounding and assessed the available evidence unfavourably. Such a meeting is not a medicine approval. Later changes to compounding rules also do not prove effectiveness in sport. US documentation does not establish authorisation for a specific product or indication in Poland. [81]

8. What is new in research?

A 2026 paper used spectroscopy to analyse the structure and behaviour of several peptides, including ipamorelin. It also examined interactions with a laboratory membrane model. This is new chemical knowledge, not a patient treatment trial. The source review through 3 November 2026 found no new large primary study changing the assessment of ipamorelin's benefits for body composition, longevity or recovery in healthy adults. [82] [81]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.